288 related articles for article (PubMed ID: 29051161)
1. Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T Cells.
Olson BM; Gamat M; Seliski J; Sawicki T; Jeffery J; Ellis L; Drake CG; Weichert J; McNeel DG
Cancer Immunol Res; 2017 Dec; 5(12):1074-1085. PubMed ID: 29051161
[TBL] [Abstract][Full Text] [Related]
2. Sequence of androgen receptor-targeted vaccination with androgen deprivation therapy affects anti-prostate tumor efficacy.
Muralidhar A; Gamat-Huber M; Vakkalanka S; McNeel DG
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38772685
[TBL] [Abstract][Full Text] [Related]
3. Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts.
Kim K; Watson PA; Lebdai S; Jebiwott S; Somma AJ; La Rosa S; Mehta D; Murray KS; Lilja H; Ulmert D; Monette S; Scherz A; Coleman JA
Clin Cancer Res; 2018 May; 24(10):2408-2416. PubMed ID: 29463549
[No Abstract] [Full Text] [Related]
4. Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer.
Ragnum HB; Røe K; Holm R; Vlatkovic L; Nesland JM; Aarnes EK; Ree AH; Flatmark K; Seierstad T; Lilleby W; Lyng H
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):753-60. PubMed ID: 24035332
[TBL] [Abstract][Full Text] [Related]
5. TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer.
Siu MK; Chen WY; Tsai HY; Chen HY; Yin JJ; Chen CL; Tsai YC; Liu YN
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):172-178. PubMed ID: 28220803
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
7. The Efflux Transporter ABCG2 Maintains Prostate Stem Cells.
Sabnis NG; Miller A; Titus MA; Huss WJ
Mol Cancer Res; 2017 Feb; 15(2):128-140. PubMed ID: 27856956
[TBL] [Abstract][Full Text] [Related]
8. Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes.
Olsen JR; Azeem W; Hellem MR; Marvyin K; Hua Y; Qu Y; Li L; Lin B; Ke X; Øyan AM; Kalland K
BMC Cancer; 2016 Jul; 16():377. PubMed ID: 27378372
[TBL] [Abstract][Full Text] [Related]
9. Targeting androgen receptor action for prostate cancer treatment: does the post-receptor level provide novel opportunities?
Heemers HV
Int J Biol Sci; 2014; 10(6):576-87. PubMed ID: 24948870
[TBL] [Abstract][Full Text] [Related]
10. Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression.
Chou FJ; Chen Y; Chen D; Niu Y; Li G; Keng P; Yeh S; Chang C
EBioMedicine; 2019 Feb; 40():504-516. PubMed ID: 30692044
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of the androgen receptor splicing in prostate cancer cells.
Liu LL; Xie N; Sun S; Plymate S; Mostaghel E; Dong X
Oncogene; 2014 Jun; 33(24):3140-50. PubMed ID: 23851510
[TBL] [Abstract][Full Text] [Related]
12. Functionality of androgen receptor-based gene expression imaging in hormone refractory prostate cancer.
Sato M; Johnson M; Zhang L; Gambhir SS; Carey M; Wu L
Clin Cancer Res; 2005 May; 11(10):3743-9. PubMed ID: 15897571
[TBL] [Abstract][Full Text] [Related]
13. Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth.
Cha TL; Qiu L; Chen CT; Wen Y; Hung MC
Cancer Res; 2005 Mar; 65(6):2287-95. PubMed ID: 15781642
[TBL] [Abstract][Full Text] [Related]
14. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
15. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer.
Koivisto P; Kononen J; Palmberg C; Tammela T; Hyytinen E; Isola J; Trapman J; Cleutjens K; Noordzij A; Visakorpi T; Kallioniemi OP
Cancer Res; 1997 Jan; 57(2):314-9. PubMed ID: 9000575
[TBL] [Abstract][Full Text] [Related]
17. Carnosic acid promotes degradation of the androgen receptor and is regulated by the unfolded protein response pathway in vitro and in vivo.
Petiwala SM; Li G; Bosland MC; Lantvit DD; Petukhov PA; Johnson JJ
Carcinogenesis; 2016 Aug; 37(8):827-838. PubMed ID: 27267997
[TBL] [Abstract][Full Text] [Related]
18. Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.
Thelen P; Heinrich E; Bremmer F; Trojan L; Strauss A
Prostate; 2013 Nov; 73(15):1699-709. PubMed ID: 23868789
[TBL] [Abstract][Full Text] [Related]
19. Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells.
Shafi AA; Putluri V; Arnold JM; Tsouko E; Maity S; Roberts JM; Coarfa C; Frigo DE; Putluri N; Sreekumar A; Weigel NL
Oncotarget; 2015 Oct; 6(31):31997-2012. PubMed ID: 26378018
[TBL] [Abstract][Full Text] [Related]
20. Amplification and co-regulators of androgen receptor gene in prostate cancer.
Golias Ch; Iliadis I; Peschos D; Charalabopoulos K
Exp Oncol; 2009 Mar; 31(1):3-8. PubMed ID: 19300409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
